Navigation Links
eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008
Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire/ -- Mr. Glynn has over 34 years of combined financial, operating and director level experience, and is well known within the life sciences industry for his role in the growth and development of several biotechnology companies. Most notably, Mr. Glynn retired from Invitrogen Corporation (Nasdaq: IVGN) in 2003 where, during his tenure with the company, he held several operating roles including CFO, President and COO and CEO. During this time, Mr. Glynn led the company through several stages of growth including an IPO, numerous financings and several acquisitions including Novex, GIBCO Life Technologies, Research Genetics and Molecular Probes. Mr. Glynn, following his retirement from Invitrogen Corporation, remained on the company's board of directors until April 2006.

"We are very pleased to be adding someone of Jim's reputation and experience to our board," said Todd R. Nelson Ph.D., eBioscience's Chief Executive Officer. "As an emerging global leader in the cellular analysis market, we are focused on growing our business operations through the development and commercialization of a diverse array of products, and also through the operational execution of several key strategic initiatives. In his role as director, Mr. Glynn will provide invaluable operating insight, financial advice and strategic guidance to ensure eBioscience remains a leader in the life sciences market place." Brian Seed Ph.D., Chairman of the board of directors for eBioscience added, "We look forward to tapping Jim's wealth of operating wisdom and the insights gleaned from his decades of senior management experience in the life science and related industries. Jim enjoys an enviable reputation among investors and professional fund managers for his business insight, strategic acumen, and proven ability to contribute guidance at the board level."

Prior to joining Invitrogen Corporation in 1998 as the company's CFO, Mr. Glynn served as CFO for Matrix Pharmaceutical, Inc. from 1995 to 1998 and as CFO for Mycogen Corporation from 1987 to 1995. Prior to that he was Vice President, Finance & Treasurer of Lubrizol Enterprises, Inc. and an Audit manager for Price Waterhouse & Co. from 1974 to 1982.

Mr. Glynn currently serves as a director for Alphatec Spine, Inc. and American Specialty Health.


'/>"/>
SOURCE eBioscience Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
2. Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest
3. IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference
4. Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call
5. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
6. Chem Rx Corporation Reports Full Year 2007 Financial Results
7. Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results
8. Genaera Corporation Announces 2007 Financial Results
9. Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results
10. Immunosyn Corporation Announces 2007 Results, Files 10KSB
11. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... 2016  Perkotek an innovation leader in attendance control systems is proud to announce ... for employers to make sure the right employees are actually signing in, and to ... ... ... ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):